Published on NAVADHI Market Research (https://www.navadhi.com)

Home > Global Medical Devices Industry Strategic Research Report 2026-2031

Global Medical Devices Industry Strategic Research Report 2026-2031

Global Medical Devices Industry Strategic Research Report 2026-2031
Publication ID: 
NAV0826029
Publication Date: 
August 31, 2026
Pages: 
266
Countries: 
Global [1]
Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

The global medical devices market reached $581.1 billion in 2025, derived as the average of four independently published market research estimates that converge tightly within a $572-586 billion range, a notably tighter convergence than found for the companion Healthcare Industry report, reflecting medical devices being a more consistently-scoped market category across research firms. This report defines the medical devices industry as diagnostic and therapeutic device manufacturing -- cardiovascular, orthopedic, diagnostic imaging, in-vitro diagnostics, surgical/robotic, patient monitoring, ophthalmic, and dental categories -- deliberately excluding pharmaceutical manufacturing and healthcare services/delivery, which are covered as separate Navadhi mother reports. The market is forecast to grow from $581.1 billion in 2025 to $825.5 billion by 2031, a compound annual growth rate of approximately 6.0%, with growth rates gently accelerating year over year -- from 4.8% in 2026 to 6.7% in 2031 -- reflecting the compounding effect of structural demand drivers rather than any single-period event-driven surge.

M&A activity across the tracked player universe has been concentrated in two strategic themes: expanding surgical robotics capabilities and reinforcing connected-care platforms. Medtronic has continued to invest in its Hugo robotic-assisted surgery platform, targeting direct competition with Intuitive Surgical's da Vinci ecosystem, while simultaneously rationalizing its portfolio through selective divestitures, including the Patient Monitoring and Respiratory Interventions business separation completed in 2024. Stryker's Mako robotic orthopedic platform remains a core M&A-integration anchor, with the company pursuing bolt-on deals in neurosurgery and endoscopy to diversify beyond its core orthopedics franchise. Boston Scientific's exceptional 20.3% FY2025 growth has been materially supported by its acquisition strategy in electrophysiology and structural heart, while Insulet and Dexcom have deepened interoperability agreements with major consumer technology platforms, reflecting the industry's accelerating shift toward closed-loop, home-managed diabetes care systems.

Scope of Global Medical Devices Industry Strategic Research Report 2026-2031

  • This report provides forecast data by value for the global medical devices industry, with 2025 as the base year and forecasting to 2031.
  • This report provides segmentation by type (In Vitro Diagnostics, Cardiovascular Devices, Diagnostic Imaging, Surgical and Minimally Invasive/Robotic Devices, Patient Monitoring and Diabetes Care, Orthopedic Devices, Ophthalmic Devices) and by end-use setting (Hospitals, Diagnostic and Imaging Centers, Ambulatory Surgical Centers, Home Healthcare, Clinics and Physician Offices).
  • This report provides region-wise and country-level forecast data across 5 regions and 16 countries.
  • This report identifies key growth drivers and inhibitors, including population aging, rising chronic disease prevalence, and the accelerating commercial penetration of surgical robotics and connected diabetes care technologies.
  • This report provides company profiles for the 25 leading medical device companies, each covering Company Overview, Key Products & Segments, Financial Performance, Business Strategy, SWOT Analysis, and Strategic Implications.
  • This report provides Porter's Five Forces, PESTLE, and SWOT analysis.
  • This report identifies key future trends through 2031.

Segment by Type

  • In Vitro Diagnostics
  • Cardiovascular Devices
  • Diagnostic Imaging
  • Surgical and Minimally Invasive/Robotic Devices
  • Patient Monitoring and Diabetes Care
  • Orthopedic Devices
  • Ophthalmic Devices

Segment by Application

  • Hospitals
  • Diagnostic and Imaging Centers
  • Ambulatory Surgical Centers
  • Home Healthcare
  • Clinics and Physician Offices

Segment by Region

  • North America (United States, Canada, Rest of North America)
  • Europe (Germany, France, United Kingdom, Italy, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, Rest of Latin America)
  • Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)

Who Can Use the Global Medical Devices Industry Strategic Research Report?

This research report is ideal for people who wish to gain a thorough understanding of the medical devices market. Some of the intended users are:

  • C-level executives and Company Directors in medical device manufacturing and distribution companies
  • Investment managers, Financial professionals, and Healthcare/MedTech sector equity analysts
  • Regulatory affairs and market access professionals tracking FDA, CE marking, and reimbursement policy
  • Hospital and healthcare system procurement executives evaluating device technology and vendors
  • Anyone operating in the global medical devices value chain
  1. 1. Executive Summary
    1. 1.1 Market Synopsis
    2. 1.2 Key Findings
    3. 1.3 Strategic Recommendations
  2. 2. Industry Overview & Forecast
    1. 2.1 Market Definition & Scope
    2. 2.2 Market Value Forecast
    3. 2.2.1 Base-Year Establishment & Methodological Confidence
    4. 2.2.2 Global Market Forecast, 2025–2031
    5. 2.2.3 Vendor-Tier Market Structure
    6. 2.3 Historical Market Review
    7. 2.3.1 Growth Through the Historic Period, 2022–2024
    8. 2.4 Market Segmentation by Device Type
    9. 2.4.1 Segmentation Overview & Structural Dynamics
    10. 2.4.2 In Vitro Diagnostics — The Largest Category by Value
    11. 2.4.3 Cardiovascular Devices — The Largest Category by Several Metrics
    12. 2.4.4 Diagnostic Imaging — A Large but Gradually Declining Share Category
    13. 2.4.5 Surgical & Minimally Invasive/Robotic Devices — The Fastest-Growing Category
    14. 2.4.6 Patient Monitoring & Diabetes Care — A Rising-Share Category
    15. 2.4.7 Orthopedic Devices — A Stable, Mature Category
    16. 2.4.8 Ophthalmic Devices — A Smaller but Stable Growth Category
    17. 2.5 Market Segmentation by End-Use Setting
    18. 2.5.1 The Structural Migration Away From Hospital-Centric Device Demand
    19. 2.5.2 Ambulatory Surgical Centres — The Fastest-Growing Setting
    20. 2.5.3 Home Healthcare — The Highest Share-Gain Setting
    21. 2.5.4 Diagnostic & Imaging Centres and Clinics — Stable Positioning
    22. 2.6 Regional Market Forecast
    23. 2.6.1 Regional Overview
    24. 2.6.2 North America — The Dominant Region
    25. 2.6.3 Asia-Pacific — The Fastest-Growing Region
    26. 2.6.4 Europe — The Third-Largest Region
    27. 2.6.5 Latin America — A Smaller but Growing Market
    28. 2.6.6 Middle East & Africa — The Smallest but Developing Region
    29. 2.7 Key Forecast Takeaways
  3. 3. Market Segmentation by Type
    1. 3.1 Segmentation Overview and Structural Framework
    2. 3.2 In Vitro Diagnostics — The Largest Category by Share Methodology
    3. 3.3 Cardiovascular Devices — The Largest Category by Absolute Value
    4. 3.4 Diagnostic Imaging — A Large Category With Declining Relative Share
    5. 3.5 Surgical and Minimally Invasive/Robotic Devices — The Fastest-Growing Category
    6. 3.6 Patient Monitoring and Diabetes Care — Rising Share Driven by Connected Devices
    7. 3.7 Orthopedic Devices — Stable Category With Steady Structural Demand
    8. 3.8 Ophthalmic Devices — Stable Niche With Consistent Growth
    9. 3.9 Dental and Wound Care Devices — Residual Category
    10. 3.10 Cross-Category Growth Rate Comparison and Strategic Implications
  4. 4. Market Segmentation by Application
    1. 4.1 Overview: End-Use Setting as the Analytical Framework
    2. 4.2 Hospitals: Dominant but Gradually Declining Share
    3. 4.3 Diagnostic and Imaging Centers: Stable and Proportionate Growth
    4. 4.4 Ambulatory Surgical Centers: The Fastest-Gaining Setting by Share
    5. 4.5 Home Healthcare: Rising Share Driven by Connected Device Adoption
    6. 4.6 Clinics and Physician Offices: Small but Structurally Stable
    7. 4.7 Research and Academic Institutes: A Residual and Declining Share
    8. 4.8 Structural Summary: The Shift Away from Hospital-Centric Demand
  5. 5. Regional Market Forecast
    1. North America
    2. Europe
    3. Asia-Pacific
    4. Latin America
    5. Middle East & Africa
  6. 6. Country-Level Market Forecast
    1. 6.1 North America
    2. 6.1.1 United States
    3. 6.1.2 Canada
    4. 6.1.3 Rest of North America
    5. 6.2 Europe
    6. 6.2.1 Germany
    7. 6.2.2 France
    8. 6.2.3 United Kingdom
    9. 6.2.4 Italy
    10. 6.2.5 Rest of Europe
    11. 6.3 Asia-Pacific
    12. 6.3.1 China
    13. 6.3.2 Japan
    14. 6.3.3 South Korea
    15. 6.3.4 India
    16. 6.3.5 Australia
    17. 6.3.6 Rest of Asia Pacific
    18. 6.4 Latin America
    19. 6.4.1 Brazil
    20. 6.4.2 Mexico
    21. 6.4.3 Rest of Latin America
    22. 6.5 Middle East & Africa
    23. 6.5.1 Saudi Arabia
    24. 6.5.2 UAE
    25. 6.5.3 South Africa
    26. 6.5.4 Rest of Middle East and Africa
  7. 7. Growth Drivers & Inhibitors
    1. 7.1 Structural Growth Drivers
    2. 7.1.1 Chronic and Acute Disease Burden
    3. 7.1.2 Minimally Invasive and Robotic Surgical Technology Adoption
    4. 7.1.3 Connected Health and Home-Based Monitoring Convergence
    5. 7.1.4 Technological Innovation and AI-Augmented Device Intelligence
    6. 7.2 Market Restraints and Inhibitors
    7. 7.2.1 Regulatory Complexity and Commercialisation Timeline Risk
    8. 7.2.2 Reimbursement Policy Exposure
    9. 7.2.3 Market Fragmentation and Pricing Dynamics
    10. 7.2.4 Supply Chain Concentration and Input Cost Volatility
    11. 7.3 Opportunities and White-Space Analysis
    12. 7.3.1 Surgical Robotics Platform Expansion
    13. 7.3.2 Connected and Ambulatory Monitoring Ecosystems
    14. 7.3.3 Emerging Market Infrastructure Development
    15. 7.3.4 Stable Category Operational Execution Opportunity
  8. 8. Key Company Profiles (Medtronic, Johnson & Johnson MedTech, Abbott Laboratories (Medical Devices), Medline Industries, Siemens Healthineers, Stryker Corporation, Becton Dickinson (BD), GE HealthCare, Philips (Health Systems), Boston Scientific, Roche Diagnostics, Baxter International, Cardinal Health (Medical Segment), Danaher (Diagnostics/Life Sciences), Zimmer Biomet, Intuitive Surgical, Terumo Corporation, Olympus Corporation, Smith+Nephew, Edwards Lifesciences, Dexcom, Hologic, Insulet Corporation, Alcon, ResMed)
    1. 8.1 Medtronic
    2. 8.1.1 Company Overview
    3. 8.1.2 Key Products & Segments
    4. 8.1.3 Financial Performance (2023–2025)
    5. 8.1.4 Business Strategy
    6. 8.1.5 SWOT Analysis
    7. 8.1.6 Strategic Implications (2025–2031)
    8. 8.2 Johnson & Johnson MedTech
    9. 8.2.1 Company Overview
    10. 8.2.2 Key Products & Segments
    11. 8.2.3 Financial Performance (2023–2025)
    12. 8.2.4 Business Strategy
    13. 8.2.5 SWOT Analysis
    14. 8.2.6 Strategic Implications (2025–2031)
    15. 8.3 Abbott Laboratories (Medical Devices)
    16. 8.3.1 Company Overview
    17. 8.3.2 Key Products & Segments
    18. 8.3.3 Financial Performance (2023–2025)
    19. 8.3.4 Business Strategy
    20. 8.3.5 SWOT Analysis
    21. 8.3.6 Strategic Implications (2025–2031)
    22. 8.4 Medline Industries
    23. 8.4.1 Company Overview
    24. 8.4.2 Key Products & Segments
    25. 8.4.3 Financial Performance (2023–2025)
    26. 8.4.4 Business Strategy
    27. 8.4.5 SWOT Analysis
    28. 8.4.6 Strategic Implications (2025–2031)
    29. 8.5 Siemens Healthineers
    30. 8.5.1 Company Overview
    31. 8.5.2 Key Products & Segments
    32. 8.5.3 Financial Performance (2023–2025)
    33. 8.5.4 Business Strategy
    34. 8.5.5 SWOT Analysis
    35. 8.5.6 Strategic Implications (2025–2031)
    36. 8.6 Stryker Corporation
    37. 8.6.1 Company Overview
    38. 8.6.2 Key Products & Segments
    39. 8.6.3 Financial Performance (2023–2025)
    40. 8.6.4 Business Strategy
    41. 8.6.5 SWOT Analysis
    42. 8.6.6 Strategic Implications (2025–2031)
    43. 8.7 Becton Dickinson (BD)
    44. 8.7.1 Company Overview
    45. 8.7.2 Key Products & Segments
    46. 8.7.3 Financial Performance (2023–2025)
    47. 8.7.4 Business Strategy
    48. 8.7.5 SWOT Analysis
    49. 8.7.6 Strategic Implications (2025–2031)
    50. 8.8 GE HealthCare
    51. 8.8.1 Company Overview
    52. 8.8.2 Key Products & Segments
    53. 8.8.3 Financial Performance (2023–2025)
    54. 8.8.4 Business Strategy
    55. 8.8.5 SWOT Analysis
    56. 8.8.6 Strategic Implications (2025–2031)
    57. 8.9 Philips (Health Systems)
    58. 8.9.1 Company Overview
    59. 8.9.2 Key Products & Segments
    60. 8.9.3 Financial Performance (2023–2025)
    61. 8.9.4 Business Strategy
    62. 8.9.5 SWOT Analysis
    63. 8.9.6 Strategic Implications (2025–2031)
    64. 8.10 Boston Scientific
    65. 8.10.1 Company Overview
    66. 8.10.2 Key Products & Segments
    67. 8.10.3 Financial Performance (2023–2025)
    68. 8.10.4 Business Strategy
    69. 8.10.5 SWOT Analysis
    70. 8.10.6 Strategic Implications (2025–2031)
    71. 8.11 Roche Diagnostics
    72. 8.11.1 Company Overview
    73. 8.11.2 Key Products & Segments
    74. 8.11.3 Financial Performance (2023–2025)
    75. 8.11.4 Business Strategy
    76. 8.11.5 SWOT Analysis
    77. 8.11.6 Strategic Implications (2025–2031)
    78. 8.12 Baxter International
    79. 8.12.1 Company Overview
    80. 8.12.2 Key Products & Segments
    81. 8.12.3 Financial Performance (2023–2025)
    82. 8.12.4 Business Strategy
    83. 8.12.5 SWOT Analysis
    84. 8.12.6 Strategic Implications (2025–2031)
    85. 8.13 Cardinal Health (Medical Segment)
    86. 8.13.1 Company Overview
    87. 8.13.2 Key Products & Segments
    88. 8.13.3 Financial Performance (2023–2025)
    89. 8.13.4 Business Strategy
    90. 8.13.5 SWOT Analysis
    91. 8.13.6 Strategic Implications (2025–2031)
    92. 8.14 Danaher (Diagnostics/Life Sciences)
    93. 8.14.1 Company Overview
    94. 8.14.2 Key Products & Segments
    95. 8.14.3 Financial Performance (2023–2025)
    96. 8.14.4 Business Strategy
    97. 8.14.5 SWOT Analysis
    98. 8.14.6 Strategic Implications (2025–2031)
    99. 8.15 Zimmer Biomet
    100. 8.15.1 Company Overview
    101. 8.15.2 Key Products & Segments
    102. 8.15.3 Financial Performance (2023–2025)
    103. 8.15.4 Business Strategy
    104. 8.15.5 SWOT Analysis
    105. 8.15.6 Strategic Implications (2025–2031)
    106. 8.16 Intuitive Surgical
    107. 8.16.1 Company Overview
    108. 8.16.2 Key Products & Segments
    109. 8.16.3 Financial Performance (2023–2025)
    110. 8.16.4 Business Strategy
    111. 8.16.5 SWOT Analysis
    112. 8.16.6 Strategic Implications (2025–2031)
    113. 8.17 Terumo Corporation
    114. 8.17.1 Company Overview
    115. 8.17.2 Key Products & Segments
    116. 8.17.3 Financial Performance (2023–2025)
    117. 8.17.4 Business Strategy
    118. 8.17.5 SWOT Analysis
    119. 8.17.6 Strategic Implications (2025–2031)
    120. 8.18 Olympus Corporation
    121. 8.18.1 Company Overview
    122. 8.18.2 Key Products & Segments
    123. 8.18.3 Financial Performance (2023–2025)
    124. 8.18.4 Business Strategy
    125. 8.18.5 SWOT Analysis
    126. 8.18.6 Strategic Implications (2025–2031)
    127. 8.19 Smith+Nephew
    128. 8.19.1 Company Overview
    129. 8.19.2 Key Products & Segments
    130. 8.19.3 Financial Performance (2023–2025)
    131. 8.19.4 Business Strategy
    132. 8.19.5 SWOT Analysis
    133. 8.19.6 Strategic Implications (2025–2031)
    134. 8.20 Edwards Lifesciences
    135. 8.20.1 Company Overview
    136. 8.20.2 Key Products & Segments
    137. 8.20.3 Financial Performance (2023–2025)
    138. 8.20.4 Business Strategy
    139. 8.20.5 SWOT Analysis
    140. 8.20.6 Strategic Implications (2025–2031)
    141. 8.21 Dexcom
    142. 8.21.1 Company Overview
    143. 8.21.2 Key Products & Segments
    144. 8.21.3 Financial Performance (2023–2025)
    145. 8.21.4 Business Strategy
    146. 8.21.5 SWOT Analysis
    147. 8.21.6 Strategic Implications (2025–2031)
    148. 8.22 Hologic
    149. 8.22.1 Company Overview
    150. 8.22.2 Key Products & Segments
    151. 8.22.3 Financial Performance (2023–2025)
    152. 8.22.4 Business Strategy
    153. 8.22.5 SWOT Analysis
    154. 8.22.6 Strategic Implications (2025–2031)
    155. 8.23 Insulet Corporation
    156. 8.23.1 Company Overview
    157. 8.23.2 Key Products & Segments
    158. 8.23.3 Financial Performance (2023–2025)
    159. 8.23.4 Business Strategy
    160. 8.23.5 SWOT Analysis
    161. 8.23.6 Strategic Implications (2025–2031)
    162. 8.24 Alcon
    163. 8.24.1 Company Overview
    164. 8.24.2 Key Products & Segments
    165. 8.24.3 Financial Performance (2023–2025)
    166. 8.24.4 Business Strategy
    167. 8.24.5 SWOT Analysis
    168. 8.24.6 Strategic Implications (2025–2031)
    169. 8.25 ResMed
    170. 8.25.1 Company Overview
    171. 8.25.2 Key Products & Segments
    172. 8.25.3 Financial Performance (2023–2025)
    173. 8.25.4 Business Strategy
    174. 8.25.5 SWOT Analysis
    175. 8.25.6 Strategic Implications (2025–2031)
  9. 9. Competitive Landscape
    1. 9.1 Competitive Landscape Overview
    2. 9.1.1 Table 1
    3. 9.2 Competitive Intensity Assessment
    4. 9.3 Key Player Strategies & Positioning
    5. 9.3.1 Strategic Group Landscape
    6. 9.3.2 Differentiation Strategies by Strategic Group
    7. 9.3.3 Selected Company Financials & Growth Positioning (FY2025)
    8. 9.3.4 Geographic Strongholds
    9. 9.3.5 M&A and Partnership Activity (2022–Present)
    10. 9.3.6 R&D and Technology Investment Trends
    11. 9.4 Competitive Dynamics & Strategic Outlook
    12. 9.4.1 Emerging Competitive Threats & Disruption Vectors
    13. 9.4.2 Consolidation vs. Fragmentation Outlook
    14. 9.4.3 Competitive Response Matrix
    15. 9.4.4 Strategic Recommendations for 2025–2031
  10. 10. Porter's Five Forces Analysis
    1. 10.1 Threat of New Entrants
    2. 10.2 Bargaining Power of Buyers
    3. 10.2.1 Key Factors
    4. 10.2.2 Market-Specific Context
    5. 10.2.3 Trend
    6. 10.2.4 Strategic Implication
    7. 10.3 Bargaining Power of Suppliers
    8. 10.4 Threat of Substitutes
    9. 10.5 Competitive Rivalry
  11. 11. PESTLE Analysis
    1. 11.1 Political Factors
    2. 11.1.1 Government Healthcare Infrastructure Investment
    3. 11.1.2 Trade Policy and Tariff Dynamics
    4. 11.2 Economic Factors
    5. 11.2.1 Structural Demand Resilience
    6. 11.2.2 Capital Equipment Purchase Timing Sensitivity
    7. 11.2.3 Healthcare Cost Containment Pressure
    8. 11.3 Social and Demographic Factors
    9. 11.3.1 Chronic Disease Prevalence as a Structural Demand Engine
    10. 11.3.2 Population Ageing and Procedural Volume Growth
    11. 11.3.3 Shifting Patient Preferences and Consumerisation of Healthcare
    12. 11.4 Technological Factors
    13. 11.4.1 Surgical Robotics Platforms
    14. 11.4.2 Artificial Intelligence in Diagnostics and Device Intelligence
    15. 11.4.3 Connected and Wearable Monitoring Devices
    16. 11.5 Legal and Regulatory Factors
    17. 11.5.1 Device-Specific Regulatory Pathways
    18. 11.5.2 Regulatory Speed as a Competitive Differentiator
    19. 11.5.3 Post-Market Surveillance and Liability Exposure
    20. 11.6 Environmental Factors
    21. 11.6.1 Manufacturing Environmental Footprint
    22. 11.6.2 End-of-Life Device Disposal and Circular Economy Considerations
  12. 12. SWOT Analysis
    1. 12.1 Introduction
    2. 12.2 Strengths
    3. 12.2.1 Scale, Diversification, and Financial Resilience of Leading Incumbents
    4. 12.2.2 Diversified Revenue Streams Across High-Growth Categories
    5. 12.2.3 Recurring Revenue Architecture and Installed Base Lock-In
    6. 12.2.4 Innovation Pipeline Depth Across Convergent Technology Platforms
    7. 12.2.5 Global Manufacturing and Distribution Infrastructure
    8. 12.3 Weaknesses
    9. 12.3.1 Regulatory Complexity and Escalating Compliance Burden
    10. 12.3.2 Portfolio Concentration Risk in Cyclically Sensitive Sub-Segments
    11. 12.3.3 Integration Risk from Aggressive M&A Activity
    12. 12.3.4 Supply Chain Vulnerability and Raw Material Dependencies
    13. 12.4 Opportunities
    14. 12.4.1 Demographic Inevitability
    15. 12.4.2 Surgical Robotics
    16. 12.4.3 Continuous Glucose Monitoring and Diabetes Management Technology Expansion
    17. 12.4.4 Artificial Intelligence Integration Across Diagnostic and Imaging Platforms
    18. 12.4.5 Emerging Market Healthcare Infrastructure Expansion
    19. 12.4.6 Portfolio Simplification and Focused Category Leadership as Value Creation Strategy
    20. 12.5 Threats
    21. 12.5.1 Pricing Pressure and Reimbursement Policy Tightening
    22. 12.5.2 Competitive Disruption from Technology Sector Entrants
    23. 12.5.3 Geopolitical Risk and Supply Chain Deglobalisation Pressures
    24. 12.5.4 Cybersecurity Vulnerabilities in Connected Device Ecosystems
    25. 12.5.5 Talent Competition and Scientific Workforce Constraints
    26. 12.6 Strategic Synthesis
  13. 13. Future Trends & Outlook
    1. 13.1 Surgical Robotics
    2. 13.2 Connected Devices and AI Integration
    3. 13.3 Site-of-Care Migration
    4. 13.4 Long-Term Structural Outlook

List of Exhibits

  • 2.1 Exhibit 2.1: Forecast of Global Market YoY Growth Rate & CAGR Summary (in %)
  • 2.2 Exhibit 2.2: Forecast of North America (in USD Bn)
  • 2.3 Exhibit 2.3: Forecast of Europe (in USD Bn)
  • 2.4 Exhibit 2.4: Forecast of Asia-Pacific (in USD Bn)
  • 2.5 Exhibit 2.5: Forecast of Latin America (in USD Bn)
  • 2.6 Exhibit 2.6: Forecast of Middle East & Africa (in USD Bn)
  • 2.7 Exhibit 2.7: Forecast of Global (in USD Bn)
  • 3.8 Exhibit 3.8: Forecast of Cardiovascular Devices (in USD Bn)
  • 3.9 Exhibit 3.9: Forecast of In Vitro Diagnostics (IVD) (in USD Bn)
  • 3.10 Exhibit 3.10: Forecast of Diagnostic Imaging (in USD Bn)
  • 3.11 Exhibit 3.11: Forecast of Orthopedic Devices (in USD Bn)
  • 3.12 Exhibit 3.12: Forecast of Surgical & Minimally Invasive/Robotic Devices (in USD Bn)
  • 3.13 Exhibit 3.13: Forecast of Patient Monitoring & Diabetes Care (in USD Bn)
  • 3.14 Exhibit 3.14: Forecast of Ophthalmic Devices (in USD Bn)
  • 3.15 Exhibit 3.15: Forecast of Dental & Wound Care Devices (in USD Bn)
  • 4.16 Exhibit 4.16: Forecast of Hospitals (in USD Bn)
  • 4.17 Exhibit 4.17: Forecast of Diagnostic & Imaging Centers (in USD Bn)
  • 4.18 Exhibit 4.18: Forecast of Ambulatory Surgical Centers (in USD Bn)
  • 4.19 Exhibit 4.19: Forecast of Home Healthcare (in USD Bn)
  • 4.20 Exhibit 4.20: Forecast of Clinics & Physician Offices (in USD Bn)
  • 4.21 Exhibit 4.21: Forecast of Other (Research & Academic Institutes) (in USD Bn)
  • 6.22 Exhibit 6.22: Forecast of North America (in USD Bn)
  • 6.23 Exhibit 6.23: Forecast of United States (in USD Bn)
  • 6.24 Exhibit 6.24: Forecast of Canada (in USD Bn)
  • 6.25 Exhibit 6.25: Forecast of Rest of North America (in USD Bn)
  • 6.26 Exhibit 6.26: Forecast of Europe (in USD Bn)
  • 6.27 Exhibit 6.27: Forecast of Germany (in USD Bn)
  • 6.28 Exhibit 6.28: Forecast of France (in USD Bn)
  • 6.29 Exhibit 6.29: Forecast of United Kingdom (in USD Bn)
  • 6.30 Exhibit 6.30: Forecast of Italy (in USD Bn)
  • 6.31 Exhibit 6.31: Forecast of Rest of Europe (in USD Bn)
  • 6.32 Exhibit 6.32: Forecast of Asia-Pacific (in USD Bn)
  • 6.33 Exhibit 6.33: Forecast of China (in USD Bn)
  • 6.34 Exhibit 6.34: Forecast of Japan (in USD Bn)
  • 6.35 Exhibit 6.35: Forecast of South Korea (in USD Bn)
  • 6.36 Exhibit 6.36: Forecast of India (in USD Bn)
  • 6.37 Exhibit 6.37: Forecast of Australia (in USD Bn)
  • 6.38 Exhibit 6.38: Forecast of Rest of Asia Pacific (in USD Bn)
  • 6.39 Exhibit 6.39: Forecast of Latin America (in USD Bn)
  • 6.40 Exhibit 6.40: Forecast of Brazil (in USD Bn)
  • 6.41 Exhibit 6.41: Forecast of Mexico (in USD Bn)
  • 6.42 Exhibit 6.42: Forecast of Rest of Latin America (in USD Bn)
  • 6.43 Exhibit 6.43: Forecast of Middle East & Africa (in USD Bn)
  • 6.44 Exhibit 6.44: Forecast of Saudi Arabia (in USD Bn)
  • 6.45 Exhibit 6.45: Forecast of UAE (in USD Bn)
  • 6.46 Exhibit 6.46: Forecast of South Africa (in USD Bn)
  • 6.47 Exhibit 6.47: Forecast of Rest of Middle East and Africa (in USD Bn)

Medtronic, Johnson & Johnson MedTech, Abbott Laboratories (Medical Devices), Medline Industries, Siemens Healthineers, Stryker Corporation, Becton Dickinson (BD), GE HealthCare, Philips (Health Systems), Boston Scientific, Roche Diagnostics, Baxter International, Cardinal Health (Medical Segment), Danaher (Diagnostics/Life Sciences), Zimmer Biomet, Intuitive Surgical, Terumo Corporation, Olympus Corporation, Smith+Nephew, Edwards Lifesciences, Dexcom, Hologic, Insulet Corporation, Alcon, ResMed

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Enterprise license fee.

 

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Enterprise license fee.

 

Enterprise License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

About Us

NAVADHI is a market research company that helps global firms differentiate themselves, break market entry barriers, track their investments, develop business strategies and plan for future by providing actionable market research intelligence that helps them succeed.

Source URL:https://www.navadhi.com/publications/global-medical-devices-industry-strategic-research-report-2026-2031

Links
[1] https://www.navadhi.com/countries/global